SC
ABBV icon

Scotia Capital’s AbbVie ABBV Stock Holding History

Scotia Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20,000
Closed -$1.09M – 797
2015
Q3 		$1.09M Buy
+20,000
New +$1.3M 0.02% 374

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Scotia Capital's ABBV Position: Q1 2026 in Review

Scotia Capital reduced its AbbVie (ABBV) stake by 2.4% in Q1 2026, selling an estimated $1.01M and leaving 183,643 shares worth $39.9M. The position accounts for 0.16% of the portfolio, ranked #89.

Scotia Capital first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $43M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Scotia Capital held 183,643 shares of AbbVie worth $39.9M as of Q1 2026.
  • Scotia Capital sold 4,561 AbbVie shares in Q1 2026, an estimated $1.01M.
  • AbbVie made up 0.16% of Scotia Capital's portfolio in Q1 2026, its #89 holding.
  • Scotia Capital first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Scotia Capital's AbbVie position peaked at $43M in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.